The New Face Of Blockbuster Drugs

Blockbuster drugs are not going away but as science and market conditions continue to evolve and unmet needs shift to new territories, their profile is likely to change again. Companies can use strategies to offset the potential shortcomings of the new blockbuster model and improve their chances of becoming the successful players of tomorrow.

Blockbusters, defined as branded prescription drugs that generate more than $1 billion annually, have served as catalysts for driving value within the global drug market during the past 15 years. Top biopharmaceutical companies have been especially reliant on these blockbusters for their growth and shareholder value creation during this time period, as development of these drugs traditionally has delivered the highest returns on R&D investments. In the early 2000s, reports began to emerge predicting the demise of the blockbuster model. Experts who held this belief cited the wave of blockbusters that were approaching the end of their patent lives and questioned pharma's ability to replenish this gap. They predicted the future pharmaceutical winners would follow a strategy in which blockbusters play a much less important role. ( See "Blockbusters To New-Engine Drugs: The Key Industry Shift," IN VIVO , July 2003 Also see "Blockbusters to New-Engine Drugs: The Key Industry Shift" - In Vivo, 1 July, 2003..) To better understand whether or not these predictions hold true, L.E.K. analyzed data from two decades of biopharmaceutical sales to assess the recent contribution of blockbusters to biopharmaceutical growth and to identify key trends reshaping the formation of blockbusters. Supporting our findings is a proprietary database that tracks the commercial path of drugs that reached or will reach blockbuster status between 1995 and 2015, and captures detailed drug information such as product characteristics, disease indications, company type and revenue performance over time. ( See sidebar, "Insight Into Market Analysis.")

Despite industry concerns about fewer opportunities to develop multibillion-dollar drugs, the number of branded drugs that reached blockbuster status has...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.